JAMA Internal Medicine

FEBRUARY 16, 2025

This randomized clinical trial evaluates optionally switching to buprenorphine as a strategy for improving pain and reducing opioids among patients prescribed high-dose, full agonist long-term opioid therapy.

Clinical Trials 103

Clinical Trials Clinical Trials Trials 103

Drug Patent Watch

FEBRUARY 16, 2025

The Future of Biosimilars: Switching Strategies for Success As the biosimilar market continues to grow, pharmaceutical companies are looking for innovative ways to stay ahead of the competition. One strategy that's gaining traction is biosimilar-to-biosimilar switching. But what does this mean, and how can you make it work for your business? Biosimilar-to-biosimilar switching involves switching patients from one biosimilar to another, often to improve efficacy, reduce costs, or enhance patient o

Marketing 94

Marketing Research Production 94

JAMA Internal Medicine

FEBRUARY 16, 2025

This Review summarizes evidence on the diagnosis and management of monoclonal gammopathy of unknown significance to guide clinical decision-making.

91

91